Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 39, 2005, Pages 6115-6119

  Wang, Chaur Shine ^a   Lin, Chih Lin ^a   Lee, Hsi Chang ^a   Chen, Kuan Yang ^a   Chiang, Ming Feng ^a   Chen, Hung Sheng ^a   Lin, Tsung Jung ^a   Liao, Li Ying ^a  

^a TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Des carboxy prothrombin; Hepatocellular carcinoma; Fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 30644467109     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i39.6115     Document Type: Article

References (33)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-16
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285
3. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985; 1: 1357-1360
4. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications, Gut 2004; 53: 744-749
5. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, Pao CC. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-267
6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-421
7. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-65
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. EASL panel of rxperts on HCC. Clinical management of hepatoceRular carcinoma. Conclusions of the barcelona-2000 EASL conference. European sssociation for the study of the liver. J Hepatol 2001; 35: 421-430
9. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-1431
10. Soulier JP, Gozin D, Lefrere JJ. A new method to assay des-gamma-carboxyprothrombin. Results obtained in 75 cases of hepatocellular carcinoma. Gastroenterology 1986; 91: 1258-1262
11. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-gamma-carboxy-prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987; 4: 357-363
12. Nakao A, Suzuki Y, Isshiki K, Kimura Y, Takeda S, Kishimoto W, Nonami T, Harada A, Takagi H. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxyprothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol 1991; 86: 62-66
13. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-1121
14. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990; 11: 481-488
15. Chan CY, Lee SD, Wu JC, Lin HC, Huang YS, Lo GH, Lee FY, Tsai YT, Lo KJ. The diagnostic value of the assay of des-gamma-carboxy prothrombin in the detection of small hepatocellular carcinoma. J Hepatol 1991; 13: 21-24
16. Kuromatsu R, Tanaka M, Shimauchi Y, Shimada M, Tanikawa K, Watanabe K, Yokoo T. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J Gastroenterol 1997; 32: 507-512
17. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-654
18. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-1648
19. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K. Measurement of serum levels of des-gcarboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 83: 812-818
20. Pugh RNH, Muray-Lyon IM, Dawson JL. Transection of the esophagus in the bleeding esophageal varices. Br J Surg 1973; 60: 648-652
21. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 2000; 47: 1654-1658
22. Nguyen MH, Garda RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-417
23. Peng YC, Chan CS, Chen GH. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 3208-3211
24. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575
25. Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211: 277-287
26. Naofumi N, Hirofumi Y, Tadao H. The natural history of hepatocellular carcinoma: a study of 100 untreated cases. Cancer 1984; 54: 1461-1465
27. Wood WJ, Rawlings M, Evans H, Lim CNH. Hepatocellular carcinoma: importance of histological classification as a prognostic factor. Am J Surg 1988; 155: 663-666
28. Douglas GF, Michael HR, Abraham S, Ronald WB. Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219: 236-247
29. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, Lee CS, Wei TC. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409
30. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64: 2117-2120
31. Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res 1968; 28: 1344-1350
32. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990-997
33. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95: 1036-1040